Texas Permanent School Fund boosted its position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 0.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,821 shares of the biotechnology company’s stock after buying an additional 201 shares during the period. Texas Permanent School Fund owned 0.07% of Momenta Pharmaceuticals worth $625,000 as of its most recent filing with the SEC.
A number of other large investors have also recently made changes to their positions in MNTA. Pacad Investment Ltd. raised its stake in shares of Momenta Pharmaceuticals by 68.7% in the fourth quarter. Pacad Investment Ltd. now owns 11,300 shares of the biotechnology company’s stock worth $170,000 after buying an additional 4,600 shares in the last quarter. A.R.T. Advisors LLC purchased a new stake in shares of Momenta Pharmaceuticals during the fourth quarter worth about $182,000. BNP Paribas Arbitrage SA raised its stake in shares of Momenta Pharmaceuticals by 13.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,570 shares in the last quarter. Karp Capital Management Corp purchased a new stake in shares of Momenta Pharmaceuticals during the first quarter worth about $221,000. Finally, Strs Ohio purchased a new stake in shares of Momenta Pharmaceuticals during the first quarter worth about $221,000. 86.05% of the stock is currently owned by institutional investors and hedge funds.
Momenta Pharmaceuticals, Inc. (MNTA) opened at 16.65 on Friday. The company’s market capitalization is $1.17 billion. Momenta Pharmaceuticals, Inc. has a 1-year low of $9.66 and a 1-year high of $19.90. The firm has a 50-day moving average price of $15.48 and a 200-day moving average price of $15.17.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.63. The firm had revenue of $26.61 million during the quarter, compared to the consensus estimate of $21.29 million. Momenta Pharmaceuticals had a negative return on equity of 8.20% and a negative net margin of 24.70%. The company’s quarterly revenue was up 34.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.35) earnings per share. On average, analysts forecast that Momenta Pharmaceuticals, Inc. will post ($1.45) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally published by WKRB News and is the property of of WKRB News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.wkrb13.com/markets/2229775/texas-permanent-school-fund-purchases-201-shares-of-momenta-pharmaceuticals-inc-mnta.html.
A number of brokerages recently issued reports on MNTA. Zacks Investment Research lowered Momenta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 24th. TheStreet raised Momenta Pharmaceuticals from a “d” rating to a “c” rating in a research report on Tuesday, February 21st. Aegis reissued a “hold” rating and issued a $17.00 target price on shares of Momenta Pharmaceuticals in a research report on Tuesday, February 21st. Leerink Swann lowered Momenta Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 target price on the stock. in a research report on Tuesday, February 21st. Finally, Stifel Nicolaus dropped their target price on Momenta Pharmaceuticals from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. Momenta Pharmaceuticals has an average rating of “Hold” and an average price target of $16.89.
In other news, President Craig A. Wheeler sold 1,852 shares of the stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $15.77, for a total value of $29,206.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $15.83, for a total value of $65,156.28. Following the completion of the sale, the president now directly owns 281,919 shares of the company’s stock, valued at $4,462,777.77. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,379 shares of company stock valued at $131,825. Company insiders own 4.40% of the company’s stock.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229775/texas-permanent-school-fund-purchases-201-shares-of-momenta-pharmaceuticals-inc-mnta.html
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.